Four non‐small‐cell lung cancer (NSCLC) registration trials were utilized to develop models
linking survival to risk factors and changes in tumor size during treatment. The purpose was …

Purpose We use changes in tumor measurements to assess response and progression,
both in routine care and as the primary objective of clinical trials. However, the variability of …

Purpose To assess new metrics of tumor-size response to predict overall survival (OS) in
colorectal cancer (CRC) in Western and Chinese patients. Patients and Methods Various …

Background Vascular endothelial growth factor (VEGF) and c-kit are highly expressed in
adenoid cystic carcinoma (ACC) and associated with biologic aggressiveness. This study …

Targeted therapeutics have challenged how imaging techniques assess tumour response to
treatment because many new agents are thought to cause cytostasis rather than cytotoxicity …

Although progression-based endpoints, such as progression-free survival, are often key
clinical trial endpoints for anticancer agents, the clinical meaning of “objective progression” …

Purpose: Little is known concerning the onset, duration, and magnitude of direct therapeutic
effects of anti–vascular endothelial growth factor (VEGF) therapies. Such knowledge would …

Advances in our understanding of cancer biology have led to the discovery of a spectrum of
new therapeutic targets. However, despite remarkable progress in the identification and …

Purpose: Neuroendocrine tumors (NET) are heterogeneous tumors with widely variable
survival. It is unknown whether they express EpCAM (epithelial cell adhesion molecule) and …

The advent of the epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies
(mAbs), cetuximab and panitumumab has expanded the range of treatment options for …